Real Life Experience With Caduet In Patients With Cardiovascular Risk Factors - Study Results

Real Life Experience With Caduet In Patients With Cardiovascular Risk Factors (EXCEL)

This study has been terminated.

( See the termination reason in detailed description. )

Study NCT00579254 Information provided by Pfizer

First Received: December 20, 2007 Last Updated: June 18, 2009 History of Changes

Study Type:	Observational
Study Design:	Cohort, Prospective
Condition:	Hypertension and Cardiovascular Risk Factors
Intervention:	Drug: CADUET (AMLODIPINE 5 mg/ATORVASTATIN 10 mg or 20 mg)

Participant Flow

Recruitment Details

Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details

Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
This was a phase 4, observational, open-label study conducted in patients who were prescribed singlepill Caduet by their treating physician per usual clinical practice. Study drug was not provided by the Sponsor.

Reporting Groups

	Description
Caduet	Patients were treated with Caduet (5/10 or 5/20 mg) in this study according to prevailing local clinical practice following the locally approved product labeled recommendations.

Participant Flow: Overall Study

	Caduet
STARTED	112
COMPLETED	0
NOT COMPLETED	112
Lost to Follow-up	39
Discontinued when study terminated	73

Baseline Characteristics

Reporting Groups

	Description
Caduet	Patients were treated with Caduet (5/10 or 5/20 mg) in this study according to prevailing local clinical practice following the locally approved product labeled recommendations.

Baseline Measures

	Caduet
Number of Participants [units: participants]	112
Age [units: years] Mean ± Standard Deviation	54.7 ± 9.6
Gender [units: participants]
Female	41
Male	71